For non-small cell lung cancer (NSCLC), the efficacy of Vx-001 can be predicted by the number of tumor-infiltrating lymphocytes (TIL): Patients with high levels of CD3+-infiltrating lymphocytes, CD8+-infiltrating lymphocytes, and GZMB+- infiltrating lymphocytes are not suitable for immunotherapy with Vx-001 [111]. Here, CD8A is linked to neoplasm.